ONT-380-206: Phase 2 Randomized, Double-Blinded, Controlled Study of tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
To compare the safety and effectiveness of Tucatinib (the study drug) vs placebo in combination with capecitabine and trastuzumab in adults with unresectable locally advanced or metastatic HER2+ Breast Cancer
unresectable locally advanced HER2+ Breast Cancer
metastatic HER2+ Breast Cancer
1. Male or female age 18 or older.
2. HER2+ confirmed breast cancer
3. Have progressed on at least one prior treatment for locally advanced unresectable or metastatic breast cancer.
4. Previously received a taxane, trastuzumab, pertuzumab, or T-DM1
Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Treatment will continue until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment. After that participants will be contacted by phone every 3 months until the end of the study.
Knight Clinical Trials Information Line
Cascadian Therapeutics, Inc.